NTI
NEUROTECH INTERNATIONAL LIMITED
$0.0140
0.00%
Market cap
$23M
Turnover
$38,879
Last price
$0.0140
Day change
0.00%
Announcements
10
Range, past year
Open 0.017 · Low 0.010 · Now 0.014 · High 0.029
Open NTI in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NTI momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
40/100
Wyckoff phase
Accumulation21d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+7.7%
1 Month
+16.7%
1 Year
-17.6%
RSI
52
Avg daily range
8.5%
NEUROTECH INTERNATIONAL LIMITED scores 40 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 21 trading days. The weekly timeframe reads Accumulation, which agrees with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -33.3%
- High volatility (ATR 8.5%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
NTI announcements
Recent price-sensitive releases.
- 2026-09-21 NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study Progress Report
- 2026-08-26 Appendix 4E & Annual Report to shareholders Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-04 Receipt of Binding Commitments for $4.5m Placement Placement | Trading Halt Lifted
- 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-31 Trading Halt Trading Halt
- 2026-07-15 Neurotech secures $3.15 million R&D tax incentive loan
- 2026-07-14 US FDA clears IND for NTI164
More Health Care stocks
Most traded in the same sector.